Inogen INC 8-K filings

Inogen Inc. announced second quarter 2026 financial results, reporting $95.1 million in revenue and raising full-year adjusted EBITDA guidance to approximately $4.0 million.

Inogen, Inc. announced the appointment of Andy Reding as its new Chief Operating Officer, effective July 6, 2026, to enhance operational execution and support global commercial strategies.

Inogen stockholders approved an amendment to the 2023 Equity Incentive Plan, authorizing an additional 750,000 shares for issuance.

Inogen announced first quarter 2026 financial results, reporting a 3.4% year-over-year revenue increase and reiterating its full-year guidance, while also authorizing a $30 million share repurchase program.

Inogen, Inc. has appointed medical device veteran Vafa Jamali to its Board of Directors as part of a cooperation agreement with Kent Lake Partners.

Inogen appointed Baxter/Hillrom veteran Jason Richardson as CFO, added senior commercial leaders, and reaffirmed its Q1 and full-year 2026 outlook.

Inogen, Inc. announced its fourth quarter and full year 2025 financial results, showcasing significant profitability improvements and authorizing a $30 million share repurchase program.

Inogen, Inc. announced preliminary unaudited revenue results for the fourth quarter and full year 2025, showing modest growth despite a delay in some customer orders.

Inogen, Inc. announced its third quarter 2025 financial results, reporting 4.0% revenue growth and raising its full-year adjusted EBITDA guidance.

Inogen, Inc. reported a 4% year-over-year revenue increase in Q2 2025, reaching $92.3 million, and raised its full-year 2025 revenue guidance.

Inogen, Inc. announced the designation of Jennifer Yi Boyer as an Executive Officer and Section 16 Officer, and the appointment and designation of Mary Wright as Chief Accounting Officer and Executive Officer, effective July 28, 2025.

Inogen Inc. stockholders approved an amended equity incentive plan and elected directors at the annual meeting on May 14, 2025.

Inogen announces a 5.5% increase in first quarter 2025 revenue, driven by international and domestic business-to-business demand.

Inogen announces a 5.5% increase in Q4 revenue and a 6.4% increase in full-year revenue for 2024, driven by strong business-to-business sales and strategic initiatives.

Inogen announces the appointment of Mira Kirti Sahney to its Board of Directors, effective January 31, 2025, following the retirement of Tom West on January 30, 2025.

Inogen and Yuwell have entered into a strategic collaboration to expand Inogen's product portfolio, enhance its innovation pipeline, and accelerate its entry into the Chinese market, alongside a $27.2 million equity investment by Yuwell.

Inogen reports preliminary unaudited revenue for Q4 and full year 2024, exceeding previous guidance with strong business-to-business growth.

Inogen, Inc. has received FDA 510(k) clearance for its SIMEOX 200 airway clearance device, leading to a $13 million milestone payment.

Inogen's third quarter 2024 results show a 5.8% increase in revenue compared to the same period last year, driven by strong business-to-business sales.

Inogen's second quarter 2024 financial results show a 6.1% increase in total revenue, driven by growth in business-to-business sales, and improved gross margins.

Inogen Inc. has entered into a transition agreement with Jason Somer, its former Executive Vice President, General Counsel and Secretary, following his separation from the company on July 19, 2024.

Inogen, Inc. has announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024, while also noting the departure of Jason Somer.

Inogen Inc. stockholders approved an amended equity incentive plan, increasing the number of shares available for issuance and removing liberal share counting rules.

Inogen Inc. has entered into a separation agreement with its former Executive Vice President, R&D and Chief Medical Officer, Stanislav Glezer, following his departure from the company.

Inogen's first quarter 2024 financial results show an 8.1% increase in total revenue, reaching $78.0 million, primarily due to strong international and business-to-business sales.

Inogen Inc. has announced the departure of Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer, effective on or before May 3, 2024.

Inogen's Q4 2023 revenue was $75.9 million, with full-year revenue at $315.7 million, reflecting a decrease compared to the previous year, but the company is focusing on future growth and profitability.

Inogen, Inc. has appointed Michael Bourque as its new Chief Financial Officer, effective March 4, 2024, succeeding interim CFO Mike Sergesketter.